Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is planning to raise up to Rs 12,000 crore through convertible debentures or a qualified institutional placement (QIP). In this regard, the company is seeking shareholder approval.

The company will use the raised fund for expansion and acquisitions. The company would allow it to strengthen its financial resources and net worth. Following the merger with Ranbaxy Pharmaceuticals, the company has been restructuring its business and rationalizing its manufacturing footprint.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.